Piramal Pharma has reported a 22.6% reduction in Scope 1 and Scope 2 emissions alongside zero Official Action Indicated observations from three USFDA inspections.

Piramal reports emissions and quality progress

Piramal Pharma has reported a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions against its FY2022 baseline in its latest sustainability report.

The company also increased renewable energy use to 41% of total energy consumption across its operations during FY2025–26.

Alongside its environmental performance, Piramal reported completing 38 regulatory inspections during the year, including three inspections by the US Food and Drug Administration (FDA) that resulted in zero Official Action Indicated (OAI) observations.

The company also completed 209 customer audits across its global manufacturing network.

Piramal said its sustainability programme is being implemented alongside investment in manufacturing, quality and digital systems.

The company has announced a US$90 million investment to expand advanced therapeutics capabilities at its Lexington and Riverview facilities.

Manufacturing and digital investment

Piramal is continuing digital transformation across its operations, including implementation of SAP S/4HANA, expansion of digital quality systems and its Catalyst NxGen programme.

The company said these initiatives are intended to support operational and quality processes across its manufacturing network.

The sustainability report also records the recycling and reuse of 2.63 lakh kilolitres of freshwater and the diversion of 65% of total waste for recycling during the reporting period.

Piramal’s decarbonisation programme is aligned with Science Based Targets initiative (SBTi)-approved targets.

The company said its sustainability framework covers four areas: business resilience, quality and excellence, responsible operations, and stakeholder centricity.

Nandini Piramal, chairperson of Piramal Pharma, said: “At Piramal Pharma, we see sustainability not simply as a responsibility, but as a catalyst for innovation, resilience and long-term growth.”

Pharmaceutical operations and sustainability

The company has set more than 50 time-bound sustainability targets across 17 material topics, covering areas including environmental performance, responsible operations and stakeholder engagement.

During FY2025–26, Piramal said 38% of critical suppliers were assessed against sustainability criteria as part of its responsible supply chain programme.

The company also reported zero data breach incidents and zero corruption cases during the reporting period, while 100% of employees completed ESG training and Code of Conduct training.

Piramal said women accounted for 30% of its board and 20.1% of its global workforce during the reporting period.

Its corporate social responsibility programmes received ₹8.98 crore during FY2025–26 and the company said its healthcare and education initiatives reached nearly 1.8 million people across 112 Aspirational Districts in India.

The sustainability report follows the Global Reporting Initiative (GRI) standards and is aligned with the Sustainability Accounting Standards Board (SASB) and United Nations Global Compact (UNGC) frameworks.

For pharmaceutical manufacturers, the report provides an overview of Piramal’s progress across environmental performance, regulatory compliance, manufacturing investment and operational systems.

The reported USFDA inspection results are particularly relevant to the company’s manufacturing operations, while the emissions and renewable-energy figures provide a measure of progress against its longer-term environmental targets.